TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00876330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support for Hypertension
Description: Clinical decision support alerts for antihypertensive therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach for Antihypertensive Therapy
Description: Automated Telephone Outreach to patients for antihypertensive medication therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support for Lipid-lowering Therapy
Description: Clinical Decision Support alerts for Lipid-lowering medication therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach for Lipid-lowering Therapy
Description: Automated telephone outreach to patients for Lipid-lowering medication therapy.
Study: NCT01892956

Intervention type: OTHER
Intervention: Nutritional intervention
Description: 2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet
Study: NCT01226927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated intermittent bolus
Description: Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
Study: NCT02713828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I: Glembatumumab Vedotin
Description: Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: Glembatumumab Vedotin
Description: In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
Study: NCT02669992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled or Hand-sewn anastomosis
Description: Randomization between stapled or hand-sewn anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapled or Hand-sewn anastomosis
Description: Randomization between stapled or hand-sewn anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh or suture stoma site closure
Description: Randomization between suture or Mesh closure of the stoma site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh or suture stoma site closure
Description: Randomization between suture or Mesh closure of the stoma site
Study: NCT03192761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction hamstrings
Description: HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction patella tendon
Description: PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction iliotibial tract
Description: TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in.
Study: NCT03813914

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sineos
Description: glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sineos
Description: glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
Study: NCT02812927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edelvaiss Multiline-8
Description: Optimised infusion line

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard infusion line
Study: NCT03052595

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of autonomous nervous system function
Description: Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of autonomous nervous system function
Description: Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Stroop test
Description: Stroop test will be used to test cognitive function

Intervention type: DIAGNOSTIC_TEST
Intervention: Stroop test
Description: Stroop test will be used to test cognitive function
Study: NCT00565123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops
Description: 0.5% levofloxacin eye drops three times daily to each eye for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levofloxacin eye drops
Description: 0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
Study: NCT04359485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycolic acids peel 70%
Description: Glycolic acid peel 70% applied in 3 coats medium depth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium chloride
Study: NCT01092910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esteem Totally Implantable Hearing System
Description: The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
Study: NCT01340573

Intervention type: DRUG
Intervention: PegIntron Pen
Description: Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.

Intervention type: DRUG
Intervention: PegIntron Pen
Description: Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.

Intervention type: DRUG
Intervention: Ribavirin
Description: Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.

Intervention type: DRUG
Intervention: Ribavirin
Description: Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
Study: NCT03263338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
Study: NCT01265927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN163L in combination with trastuzumab
Description: GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
Study: NCT03263338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
Study: NCT03214406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Advance White Brilliant Sparkle (Test product)
Description: 20% sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection Regular Toothpaste (Negative Control)
Description: Negative control
Study: NCT00492336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline (Pharmacodynamics)
Description: Rasagiline 1 mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet each day
Study: NCT01418079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 MedTech cerebral oximeter (Oxygen desaturation)
Description: Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study: NCT04310566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens (senofilcon A c3)
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens (senofilcon A c3)
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL
Study: NCT03227666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
Study: NCT04165499

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP026)
Description: Each participant will consume 2 capsules daily, in the morning and in the evening.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Each participant will consume 2 capsules daily, in the morning and in the evening.
Study: NCT04067414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells.
Study: NCT03167021

Intervention type: OTHER
Intervention: Survey
Description: This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
Study: NCT00429169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
Study: NCT04443309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg,iv,d1,q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
Study: NCT03460561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block (TEA)
Description: Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block (RSB)
Description: Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side.
Study: NCT03964324

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractioned Exhaled Nitrogen Oxide measurements
Description: Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
Study: NCT02355210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria adolescentis BD1
Description: packet containing 10\^9 cells of Bifidobacteria adolescentis BD1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria animalis subsp. lactis BB-12
Description: packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria adolescentis BD1 and galactooligosaccharide
Description: packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
Study: NCT00847951

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D Ultrasound Imaging
Description: Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
Study: NCT03613766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Study: NCT00561912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 15 mg/m\^2 IV Daily over one hour for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
Study: NCT02934399

Intervention type: OTHER
Intervention: 27 hour subcutaneous fluid sampling
Description: One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours).

Intervention type: OTHER
Intervention: 27 hour subcutaneous fluid sampling
Description: One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours).
Study: NCT01640249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3006072
Description: Capsules administered orally
Study: NCT03673917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: The educational video on skin cancer for cosmetologists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video
Description: A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
Study: NCT03390335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure
Description: Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Gas
Description: Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
Study: NCT02591524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar and Nasal Lavage
Description: A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
Study: NCT01804179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intervention (SI) Educational Materials
Description: Screen for Life brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARES Intervention Educational Materials
Description: Newly developed digital video disc (DVD) and booklet
Study: NCT02355210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide
Description: packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: galactooligosaccharide
Description: 5 g galactooligosaccharide
Study: NCT01428622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution
Study: NCT02440256

Intervention type: OTHER
Group type: OTHER
Intervention: Expanded HIV care in Opioid Substitution Treatment
Description: The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.

Intervention type: OTHER
Group type: OTHER
Intervention: Expanded HIV care in Opioid Substitution Treatment
Description: The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.

Intervention type: OTHER
Group type: OTHER
Intervention: Expanded HIV care in Opioid Substitution Treatment
Description: The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.